Pertussis disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: PRT037 MIFTS: 64	Pertussis Categories: Infectious diseases, Oral diseases, Rare diseases, Respiratory diseases, Smell/Taste diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Pertussis

MalaCards integrated aliases for Pertussis:

Name: Pertussis ¹¹ ¹⁹ ⁵⁸ ⁷⁵ ²⁸ ² ¹⁴ ⁷¹ ⁷⁵ ³³

Whooping Cough ¹¹ ¹⁹ ⁵⁸ ⁷⁵ ⁴¹ ² ¹⁴ ¹⁶ ³¹ ³³

Bordetella Infections ⁴³ ¹⁶ ⁷¹

Bordetella Pertussis Infection ¹⁹ ³³

Bordetella Infection ¹¹ ³³

Whooping Cough Due to Unspecified Organism ⁷¹

Infection Due to Bordetella Parapertussis ³³

Whooping Cough Due to B. Parapertussis ³³

Whooping Cough, Unspecified Organism ³³

Wc - [whooping Cough] ³³

Wc - Whooping Cough ¹¹

Tussis Convulsiva ³³

Bordetellosis ³³

Characteristics:

Prevelance:

Whooping Cough: 1-9/100000 (Europe, Austria, Bulgaria, Estonia, Finland, Croatia, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Portugal, Slovenia, Spain, Sweden, United Kingdom) 1-5/10000 (Belgium, Czech Republic, Denmark, Germany, Netherlands, Norway, Poland, Slovakia) 1-9/1000000 (Cyprus, Greece, Hungary, Malta, Romania) ⁵⁸

Age Of Onset:

Whooping Cough: All ages ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases
Anatomical: Respiratory diseases Smell/Taste diseases Oral diseases

See all MalaCards categories (disease lists)

ICD10: ³¹ ³²

Certain infectious and parasitic diseases

Other bacterial diseases

Whooping cough

Whooping cough due to Bordetella parapertussis

Whooping cough due to Bordetella pertussis

Whooping cough due to other Bordetella species

Whooping cough, unspecified

ICD11: ³³

Certain infectious or parasitic diseases

Other bacterial diseases

Whooping cough

Other specified whooping cough

Whooping cough due to Bordetella parapertussis

Whooping cough due to Bordetella pertussis

Whooping cough, unspecified

Orphanet: ⁵⁸

Rare infectious diseases

External Ids:

Disease Ontology ¹¹ DOID:1116

MeSH ⁴³ D001885

SNOMED-CT ⁶⁸ 26484003

ICD10 ³¹ A37 A37.0 A37.1 more

MESH via Orphanet ⁴⁴ D014917

ICD10 via Orphanet ³² A37.0 A37.1 A37.8 more

UMLS via Orphanet ⁷² C0043167 C0043168

Orphanet ⁵⁸ ORPHA1489

EFO ¹⁶ EFO_0000650 EFO_1001275

ICD11 ³³ 1287021540 2064398473 2064398473/other more

UMLS ⁷¹ C0006015 C0043167 C0043168

Sources

Summaries for Pertussis

MedlinePlus: ⁴¹ What is whooping cough? Whooping cough, or pertussis, is a respiratory infection that can cause coughing fits. In serious cases, the coughing can become violent and rapid. You may cough so hard that you vomit. The name of the disease comes from the whooping noise you might make when you try to breathe in after coughing. Whooping cough is very contagious and can affect anyone. But it can be especially serious in babies who did not yet get the vaccine. About half of babies under age one who get whooping cough need care in the hospital. What causes whooping cough? Whooping cough is caused by a type of bacteria called Bordetella pertussis. It spreads from person to person. People who have pertussis usually spread it through coughing, sneezing, or breathing very close to someone. It can also sometimes be spread by touching an infected surface and then touching your nose or mouth. If you get pertussis, you are contagious for about 2 weeks after you start coughing. Antibiotics may shorten the time that you are contagious. What are the symptoms of whooping cough? The symptoms of pertussis usually start within 5 to 10 days after you are exposed. But sometimes you may not get symptoms until up to 3 weeks later. Whooping cough usually starts with cold-like symptoms. They may last for 1 to 2 weeks and can include: Runny nose Mild fever Mild, occasional cough The early symptoms in babies can be different. They may only cough a little bit, or they may not cough at all. Babies may have apnea, which means that there is a pause in breathing. They may start to turn blue. If this happens, get medical care for your baby right away. As whopping cough gets worse, the symptoms may include: Fits of many, rapid coughs followed by a high-pitched "whoop" sound Vomiting during or after coughing fits Exhaustion after coughing fits The coughing fits get worse and start happening more often, especially at night. You may have them for up to 10 weeks or more. Recovery from this can happen slowly. Your cough gets milder and happens less often. The coughing fits can come back if you have another respiratory infection, even months after you first got whooping cough. How is whooping cough diagnosed? Your health care provider may use many tools to diagnose whooping cough: A medical history, which includes asking about your symptoms A physical exam A lab test which involves taking a sample of mucus from the back of the throat through the nose. This may be done with a swab or syringe filled with saline. The sample is tested for the bacteria that causes whooping cough. Blood test Chest x-ray What are the treatments for whooping cough? The treatment for whooping cough is usually antibiotics. Early treatment is very important. It may make your infection less serious and can also help prevent spreading the disease to others. Treatment after you have been sick for 3 weeks or longer may not help. The bacteria are gone from your body by then, even though you usually still have symptoms. This is because the bacteria have already done damage to your body. Whooping cough can sometimes be very serious and require treatment in the hospital. Can whooping cough be prevented? Vaccines are the best way to prevent whooping cough. There are two vaccines in the United States that can help prevent whooping cough: DTaP and Tdap. These vaccines also provide protection against tetanus and diphtheria. Babies and other people at high risk serious disease should be kept away from people who have whooping cough. Sometimes health care providers give antibiotics to family members of people who have had whooping cough or people who have been exposed to it. The antibiotics may prevent them from getting the disease. You may also help prevent the spread of whooping cough (and other respiratory diseases) by: Washing your hands often with soap and water. You can use an alcohol-based hand rub if soap and water are not available. Avoiding touching your face with unwashed hands Cleaning and disinfecting surfaces that you frequently touch, including toys Covering coughs and sneezes with a tissue or upper shirt sleeve, not hands Staying home when sick Avoiding close contact with people who are sick Centers for Disease Control and Prevention

MalaCards based summary: Pertussis, also known as whooping cough, is related to respiratory failure and bronchiolitis, and has symptoms including fever, pruritus and snoring. An important gene associated with Pertussis is OPRM1 (Opioid Receptor Mu 1), and among its related pathways/superpathways are Innate Immune System and Apoptotic Pathways in Synovial Fibroblasts. The drugs Montelukast and Aluminium phosphate have been mentioned in the context of this disorder. Affiliated tissues include respiratory tract, smooth muscle and dorsal root ganglion, and related phenotypes are homeostasis/metabolism and nervous system

GARD: ¹⁹ A rare bacterial infectious disease characterized by severe coughing paroxysms with inspiratory whooping and posttussive vomiting, caused by infection with Bordetella pertussis. After a variable incubation time, the clinical course progresses through a catarrhal stage with sore throat, nasal congestion, rhinorrhea, and mild progressive dry cough, a paroxysmal stage with the typical paroxysmal coughing, and finally convalescence. Disease duration is usually 2-3 months, often with milder presentation in adolescents and adults than in infants and children.

Orphanet: ⁵⁸ A rare bacterial infectious disease characterized by severe coughing paroxysms with inspiratory whooping and posttussive vomiting, caused by infection with Bordetella pertussis. After a variable incubation time, the clinical course progresses through a catarrhal stage with sore throat, nasal congestion, rhinorrhea, and mild progressive dry cough, a paroxysmal stage with the typical paroxysmal coughing, and finally convalescence. Disease duration is usually 2-3 months, often with milder presentation in adolescents and adults than in infants and children.

CDC: ² Pertussis, also known as whooping cough, is a highly contagious respiratory disease. It is caused by the bacterium Bordetella pertussis. Pertussis is known for uncontrollable, violent coughing which often makes it hard to breathe. After cough fits, someone with pertussis often needs to take deep breaths, which result in a "whooping" sound. Pertussis can affect people of all ages, but can be very serious, even deadly, for babies less than a year old. The best way to protect against pertussis is by getting vaccinated

Disease Ontology: ¹¹ A commensal bacterial infectious disease that results in inflammation located in respiratory tract, has material basis in Bordetella pertussis, or has material basis in Bordetella parapertussis, which produce toxins that paralyze the cilia of the respiratory epithelial cells. The infection is characterized by a prolonged, high-pitched, deeply indrawn breath (whoop).

Wikipedia: ⁷⁵ Whooping cough, also known as pertussis or the 100-day cough, is a highly contagious bacterial disease.... more...

Sources

Related Diseases for Pertussis

Diseases related to Pertussis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 648)

#	Related Disease	Score	Top Affiliating Genes
1	respiratory failure	31.1	TLR4 JUN CCL5 CCL2 CCL11
2	bronchiolitis	30.8	TLR4 CCL5 CCL2 CCL11
3	viral infectious disease	30.8	TLR4 CXCR4 CCL5 CCL2
4	pneumonia	30.6	TLR4 CCL5 CCL2 CCL11
5	allergic asthma	30.4	TLR4 ITGB2 CCL5 CCL11
6	otitis media	30.4	TLR4 CCL5 CCL2 CCL11
7	insulin-like growth factor i	30.4	SST MAPK1 EGF AKT1
8	human immunodeficiency virus type 1	30.3	CXCR4 CCL5 CCL2 CCL11
9	neuroblastoma	30.3	SST MAPK1 JUN EGF CXCR4 AKT1
10	bacterial infectious disease	30.2	TLR4 ITGB2 FPR1 CCL2
11	proteasome-associated autoinflammatory syndrome 1	30.2	TLR4 CCL5 CCL2 CCL11
12	bronchial disease	30.2	TLR4 CCL5 CCL2 CCL11
13	pheochromocytoma	30.2	SST MAPK1 JUN EGF ADCY10
14	rapidly involuting congenital hemangioma	30.1	GNAQ GNA14
15	myocarditis	30.1	TLR4 ITGB2 CCL5 CCL2 AKT1
16	toxic encephalopathy	30.0	TLR4 JUN CCL2 AKT1
17	breast adenocarcinoma	30.0	JUN EGF CCL2 AKT1
18	osteogenic sarcoma	30.0	MAPK1 JUN EGF CXCR4 AKT1 ADCY10
19	duodenal ulcer	29.9	TLR4 SST EGF
20	q fever	29.9	TLR4 CCL5 CCL2
21	conjunctivitis	29.9	TLR4 CCL2 CCL11
22	asthma	29.8	TLR4 JUN ITGB2 CXCR4 CCL5 CCL2
23	dermatitis, atopic	29.8	TLR4 CCL5 CCL2 CCL11
24	immune deficiency disease	29.8	JUN ITGB2 CXCR4 CCL5 CCL2 CCL11
25	chronic asthma	29.8	TLR4 CCL5 CCL11
26	respiratory allergy	29.8	TLR4 CCL5 CCL11
27	hyper ige syndrome	29.7	TLR4 FPR1 CCL11
28	arteriosclerosis	29.6	TLR4 CCL5 CCL2 CCL11
29	cystitis	29.6	TLR4 JUN EGF CCL2
30	high grade glioma	29.5	FPR1 EGF CXCR4 AKT1
31	severe acute respiratory syndrome	29.5	TLR4 CCL5 CCL2
32	status epilepticus	29.5	SST JUN ADORA1
33	neutropenia	29.5	TLR4 FPR1 CXCR4 AKT1
34	dilated cardiomyopathy	29.4	TLR4 MAPK1 JUN GNAQ CCL2 AKT1
35	inflammatory bowel disease	29.4	TLR4 SST JUN ITGB2 EGF CCL5
36	hypertension, essential	29.4	TLR4 SST JUN GNAQ EGF CCL5
37	cystic fibrosis	29.4	TLR4 JUN EGF CCL5 CCL2 CCL11
38	peripheral nervous system disease	29.2	TLR4 SST OPRM1 JUN EGF CXCR4
39	eye disease	29.2	TLR4 JUN GNAQ EGF CCL5 CCL2
40	rheumatoid arthritis	29.0	TLR4 MAPK1 JUN ITGB2 GNAQ CXCR4
41	interstitial lung disease 2	29.0	TLR4 JUN EGF CXCR4 CCL5 CCL2
42	diphtheria	11.5
43	tetanus	11.3
44	bordetella parapertussis whooping cough	11.0
45	poliomyelitis	10.9
46	haemophilus influenzae	10.9
47	cholera	10.8
48	measles	10.7
49	hepatitis b	10.6
50	primary agammaglobulinemia	10.6

Graphical network of the top 20 diseases related to Pertussis:

Sources

Symptoms & Phenotypes for Pertussis

UMLS symptoms related to Pertussis:

fever; pruritus; snoring; coughing

GenomeRNAi Phenotypes related to Pertussis according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	no effect	GR00402-S-1	10.18	ADCY10 ADORA1 AKT1 CCL11 CCL2 CCL5
2	no effect	GR00402-S-2	10.18	ADCY10 AKT1 CCL11 CCL2 CCL5 EGF

MGI Mouse Phenotypes related to Pertussis:

⁴⁵ (show all 12)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.33	ADCY10 ADORA1 AKT1 CCL2 CXCR4 FPR1
2	nervous system	MP:0003631	10.31	ADORA1 AKT1 CCL2 CXCR4 GNAI1 GNAQ
3	normal	MP:0002873	10.29	ADORA1 AKT1 CCL11 CCL2 EGF GNA15
4	immune system	MP:0005387	10.27	AKT1 CCL11 CCL2 CCL5 CXCR4 EGF
5	growth/size/body region	MP:0005378	10.25	ADORA1 AKT1 CCL2 CXCR4 EGF GNA15
6	cardiovascular system	MP:0005385	10.14	ADCY10 ADORA1 AKT1 CCL2 CXCR4 GNA15
7	adipose tissue	MP:0005375	10.02	AKT1 CCL2 CXCR4 GNAZ OPRM1 SST
8	reproductive system	MP:0005389	10	ADCY10 AKT1 CCL2 CXCR4 EGF GNA15
9	respiratory system	MP:0005388	9.92	ADORA1 AKT1 CCL11 CXCR4 GNAQ JUN
10	hematopoietic system	MP:0005397	9.86	ADORA1 AKT1 CCL11 CCL2 CCL5 CXCR4
11	skeleton	MP:0005390	9.85	AKT1 CCL2 CXCR4 GNAI1 GNAQ ITGB2
12	integument	MP:0010771	9.44	ADORA1 AKT1 CCL2 CXCR4 EGF GNA15

Sources

Drugs & Therapeutics for Pertussis

Drugs for Pertussis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 62)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Montelukast

Approved

Phase 4

158966-92-8

5281040

Aluminium phosphate

Approved, Investigational

Phase 4

7784-30-7

Edetate calcium disodium anhydrous

Approved, Vet_approved

Phase 4

62-33-9, 60-00-4

6049

Iron

Approved

Phase 4

7439-89-6

29936

Pentetic acid

Approved

Phase 4

67-43-6

Leukotriene Antagonists

Phase 4

Hormones

Phase 4

Anti-Asthmatic Agents

Phase 4

Hormone Antagonists

Phase 4

Respiratory System Agents

Phase 4

Vaccines

Phase 4

Immunologic Factors

Phase 4

Adjuvants, Immunologic

Phase 4

Gastrointestinal Agents

Phase 4

Antitoxins

Phase 4

Anti-Ulcer Agents

Phase 4

Antacids

Phase 4

Fibrinolytic Agents

Phase 4

Anticoagulants

Phase 4

Iron Chelating Agents

Phase 4

Antidotes

Phase 4

Protective Agents

Phase 4

Chelating Agents

Phase 4

Calcium, Dietary

Phase 4

Immunoglobulins

Phase 4

Antibodies

Phase 4

Calcium

Nutraceutical

Phase 4

7440-70-2

271

Lactitol

Approved, Investigational

Phase 3

585-86-4

157355

Deferiprone

Approved

Phase 3

30652-11-0

2972

Aluminum sulfate

Approved

Phase 2, Phase 3

10043-01-3

Heptavalent Pneumococcal Conjugate Vaccine

Phase 3

Immunoglobulins, Intravenous

Phase 3

gamma-Globulins

Phase 3

Rho(D) Immune Globulin

Phase 3

Pharmaceutical Solutions

Phase 3

Cathartics

Phase 3

Laxatives

Phase 3

Somatomedin B

Phase 3

Taxane

Phase 3

108169

Hemagglutinins

Phase 2, Phase 3

Agglutinins

Phase 2, Phase 3

PENTA

Phase 3

Aluminum hydroxide

Approved, Investigational

Phase 2

21645-51-2

Azithromycin

Approved

Phase 2

83905-01-5

447043

Monophosphoryl lipid A

Phase 1, Phase 2

Antibiotics, Antitubercular

Phase 2

Cathine

Approved, Experimental, Illicit, Vet_approved, Withdrawn

14838-15-4, 492-39-7

131954576 4786 26934

Guaifenesin

Approved, Investigational, Vet_approved

93-14-1

3516

BCG vaccine

Approved, Investigational

Fluspirilene

Approved, Investigational

1841-19-6

3396

Interventional clinical trials:

(show top 50) (show all 327)

#	Name	Status	NCT ID	Phase	Drugs
1	Optimising the Timing of Whooping Cough Immunisation in MUMs	Unknown status	NCT03908164	Phase 4
2	The Influence of BCG Vaccine as a Booster TDaP-IPV Vaccination: an Explorative Study	Unknown status	NCT02771782	Phase 4
3	A Double Blind Randomised Placebo Controlled Trial of Montelukast in the Treatment of Acute Persistent Cough in Young People and Adults in Primary Care	Unknown status	NCT01279668	Phase 4	Montelukast;Placebo
4	Clinical Study to Generate a Set of Data Characterising Clinical Events, Physiological Responses, and Innate and Adaptive Immune Responses Following a Single IM Immunisation With Boostrix® or Placebo in Healthy Adults	Unknown status	NCT02555540	Phase 4
5	An Immunogenicity and Safety Study of Combined Adsorbed Tetanus, Low Dose Diphtheria and Acellular Pertussis Vaccine (Td5ap and Td1aP) Given as a School-leaving Booster to 14-15-year-old Children Primed With a Five Component Acellular Pertussis Vaccine at 3, 5 and 12 Months of Age, and a Booster Dose at 5½ Years of Age	Unknown status	NCT00870350	Phase 4
6	A Prospective, Open-label, Interventional Phase IV Study to Assess the Safety of EupentaTM Inj. {Fully Liquid Pentavalent Vaccine, Adsorbed Diphtheria-Tetanus-whole-cell Pertussis-Hepatitis B (rDNA [Recombinant-deoxyribonucleic Acid])-Haemophilus Influenzae Type b Conjugate Vaccine}	Unknown status	NCT04056728	Phase 4
7	Safety and Immunogenicity of Adult Formulation Tetanus and Diphtheria Toxoids Adsorbed Combined With Acellular Pertussis (Tdap) Vaccine Following Blood and Morrow Transplantation in Adults	Unknown status	NCT00336115	Phase 4
8	Open Label Multicentric Randomized Phase IV Post Marketing Safety, Immunogenicity and Lot-to-Lot Consistency Analysis of Shan 5 [DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine] in Indian Infants	Unknown status	NCT00877357	Phase 4
9	The Efficacy and Safety of Vaccination Against Pertussis. Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis	Unknown status	NCT01301703	Phase 4
10	Comparison of Two Vaccinal Schemes for DTP-Pertussis-Hib Primo-immunisation in Very Preterm-born Neonates: a Randomised Bicentric Controlled Study	Unknown status	NCT02179996	Phase 4
11	A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Immunogenicity and Safety of Combined Immunization of Sabin-strain Inactivated Polio Vaccine (sIPV), Diphtheria, Tetanus, Pertussis Vaccine (DTaP) and Measles, Moms and Rubella Vaccine (MMR)	Unknown status	NCT04638985	Phase 4
12	A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Safety and Immunogenicity of Combined Immunization of Sabin-strain Inactivated Polio Vaccine (sIPV), Diphtheria, Tetanus, Pertussis (DTaP) Vaccine and Live Attenuated Hepatitis A Vaccine (HepA)	Unknown status	NCT04636827	Phase 4
13	Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents	Completed	NCT01629589	Phase 4
14	Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose	Completed	NCT01439165	Phase 4
15	A Single Blind, Multicentric, Comparative, Vaccine Interchangeability Trial of Shan 5 (Liquid) and Easy Five (Liquid) [Diphtheria-Tetanus- Pertussis, Hepatitis B and Hib Pentavalent Combination Vaccines] in Indian Infants.	Completed	NCT00674908	Phase 4
16	Pertussis Vaccination in Pregnant Women: Implementation and Evaluation of Different Models of Vaccination Dispensation	Completed	NCT03909126	Phase 4
17	Safety and Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (ADACEL®) in Persons ≥65 Years of Age	Completed	NCT00457249	Phase 4
18	Immunogenicity and Safety of Meningococcal (Groups A, C, Y, and W-135) Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Adolescents in the US When Administered Concomitantly With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap Vaccine)	Completed	NCT00777257	Phase 4
19	Impact of Pertussis Vaccination in Pregnancy on Maternal Protection Offered to Young Infants	Completed	NCT01698346	Phase 4
20	Evaluation of GSK Biological's dTpa-IPV Booster Vaccine in Children and Adolescents, 5 Years After Previous dTpa-IPV Boosting.	Completed	NCT00635128	Phase 4
21	Safety and Immunogenicity of DAPTACEL® (CP10/5/5/3DT Aventis Pasteur 5-component Pertussis Vaccine in Combination With Tetanus and Diphtheria Toxoids Adsorbed) Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ (HCP20/20/5/3DT-mIPV//PRP-T)	Completed	NCT00802867	Phase 4
22	Immunological Effects of an Acellular Pertussis Booster Vaccination in Children, Young Adults and Elderly With Different Immunisation Background. An International Study in Finland, the Netherlands and the United Kingdom	Completed	NCT03697798	Phase 4
23	Open Clinical Study to Assess the Immune Response and Safety of a Booster Dose (5th Dose) of a Combination Vaccine Against Diphteria-Tetanus-Pertussis-Polio Given to Healthy Adolescents 15-16 Years of Age.	Completed	NCT00514059	Phase 4	Boostrix polio
24	Immune Responses in Adults to Revaccination With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (ADACEL®) 10 Years After a Previous Dose	Completed	NCT00712959	Phase 4
25	Evaluation of GSK Biologicals' dTpa Booster Vaccine in Adults, Given 10 Years After Previous dTpa Boosting.	Completed	NCT00548171	Phase 4
26	A Randomised Controlled Trial Comparing Two Pertussis-containing Vaccines in Pregnancy and Vaccine Responses in UK Mothers and Their Infants	Completed	NCT02145624	Phase 4	Repevax;Boostrix-IPV
27	An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.	Completed	NCT01659996	Phase 4
28	An Open Label Multicentric Study to Evaluate the Immunogenicity and Safety of Indigenously Developed DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine (Shan 5) in Indian Infants.	Completed	NCT00617812	Phase 4
29	Evaluation of GSK Biologicals' dTpa Booster Vaccine in Young Adults 10 Years After Previous dTpa Boosting.	Completed	NCT00610168	Phase 4
30	Non-specific Effects of Vaccines - In Search of the Immunological Background	Completed	NCT00168545	Phase 4
31	A Phase III/IV Randomised Open-label Study and Comparison of the Immunogenicity and Safety of a Single Adolescent Booster Dose of a Meningococcal Group C Conjugate-containing Booster Vaccine (Meningitec™, OR NeisVac-C™ , OR Menitorix™), When Given Concurrently With an Acellular Pertussis-containing Booster Vaccine (Repevax™ or IPV-Boostrix™)	Completed	NCT02526394	Phase 4	Pertussis containing vaccine
32	Immunogenicity and Safety of the Sanofi Pasteur's DTacP-IPV Combined Vaccine (TETRAXIM™) Given as a Booster Dose at 4 to 6 Years of Life in Children Previously Vaccinated With PENTAXIM™ in the Study E2I34	Completed	NCT01031303	Phase 4
33	Safety Among Adolescents and Adults of Revaccination With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®) 4 to 5 Years After a Previous Dose	Completed	NCT00347958	Phase 4
34	Comparison in US Adolescents of the Safety and Immunogenicity of Two Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccines: ADACEL™ and BOOSTRIX®	Completed	NCT00319553	Phase 4
35	Reactogenicity of Acellular Pertussis Vaccine Booster in Adolescents Who Have Received 5 Prior Doses of BIKEN Acellular Pertussis Vaccine in Combination With Diphtheria and Tetanus Toxoids (TRIPEDIA®) or Who Have Received Primary Vaccination With 3 Doses of Whole-Cell Pertussis Vaccine, Plus at Least 1 Pertussis Booster Vaccination	Completed	NCT00304265	Phase 4
36	Safety & Immunogenicity of a Booster Dose of dTPa Vaccine (Boostrix®) Co-admnd. With Aventis Pasteur's Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Vaccine (Menactra™) vs Admn. of Either Vaccine Alone in Healthy Adolescents	Completed	NCT00282295	Phase 4
37	Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand	Completed	NCT00255021	Phase 4
38	Regulatory Post-Marketing Surveillance (PMS) Study for ADACEL™ (Adsorbed Diphtheria, Tetanus Toxoids and Component Pertussis Combined Vaccine for Adult)	Completed	NCT01137435	Phase 4
39	Immunogenicity and Safety Study of GSK Biologicals' Combined Diphtheria-tetanus-acellular Pertussis-hepatitis B-inactivated Polio-virus and Haemophilus Influenzae Type b Vaccine (Infanrix Hexa™) (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery	Completed	NCT02422264	Phase 4	Prevnar13
40	Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand	Completed	NCT02408926	Phase 4
41	Regulatory Post-Marketing Surveillance (PMS) Study for TETRAXIM™(Combined Vaccine of Adsorbed Diphtheria, Tetanus, Acellular Pertussis and Enhanced Inactivated Poliomyelitis)	Completed	NCT01437423	Phase 4
42	A Phase IV, Single-blind, Randomized, Controlled, Monocentric Study to Assess the Interchangeability of Quinvaxem (DTwP-HepB-Hib) as the 2nd and 3rd Dose After Initial Vaccination With Tritanrix HB+Hib (DTwP-HepB/Hib) With Respect to Safety and Immunogenicity in Healthy Infants at 6, 10 and 14 Weeks of Age	Completed	NCT01357720	Phase 4
43	Immunogenicity and Safety Study of a Booster Dose of GSK Biologicals' Infanrix Hexa™ (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery	Completed	NCT02853929	Phase 4
44	Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids Co-administered With GSK Biologicals' Human Rotavirus (HRV) Vaccine Rotarix (GSK444563) in Healthy Infants	Completed	NCT02907216	Phase 4
45	Safety and Immunogenicity of Adacel® Vaccine Administered to Persons 10 Years of Age	Completed	NCT01311557	Phase 4
46	Safety of the DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM®) Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China	Completed	NCT01491087	Phase 4
47	Adacel® (TdaP-Tetanus, Diphtheria, Acellular Pertussis) Booster Vaccination of Acellular Pertussis Vaccine-primed Individuals for Cell Mediated Immunity Assay Development	Completed	NCT04543669	Phase 4
48	Phase IV, Open Label Trial to Evaluate Immunogenicity of Tdap Vaccine in Post-Partum Women to Optimize Vaccination Schedule for Women Who May Have a Subsequent Child	Completed	NCT01711645	Phase 4
49	A Prospective, Randomized, Open-label Clinical Trial to Assess the Safety and Immunogenicity of Simultaneous vs Sequential Administration of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine and Inactivated Influenza Vaccine in Pregnant Women - Pilot	Completed	NCT02783170	Phase 4
50	Post-marketing, Randomized, Open-label Study to Assess the Immunogenicity and Safety of Concomitant Administration of V260 and Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Japanese Healthy Infants	Completed	NCT01926015	Phase 4

Search NIH Clinical Center for Pertussis

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

ERYTHROMYCIN PWDR

Guaifenesin

Cochrane evidence based reviews: bordetella infections

Sources

Genetic Tests for Pertussis

Genetic tests related to Pertussis:

#	Genetic test	Affiliating Genes
1	Pertussis ²⁸

Sources

Anatomical Context for Pertussis

Organs/tissues related to Pertussis:

FMA: Respiratory Tract

MalaCards : Smooth Muscle, Dorsal Root Ganglion, Endothelial, Bone Marrow, Neutrophil, Cardiac Myocytes, Pituitary

Sources

Publications for Pertussis

Articles related to Pertussis:

(show top 50) (show all 30047)

#	Title	Authors	PMID	Year
1	Prior exposure to B. pertussis shapes the mucosal antibody response to acellular pertussis booster vaccination. ⁶² ⁴¹	van Schuppen E...Diavatopoulos DA	36460655	2022
2	Knowledge and Willingness toward Vaccination among Pregnant Women: Comparison between Pertussis and Influenza. ⁶² ⁴¹	Jiang F...Qu B	36360959	2022
3	Pertussis prevalence among adult patients with acute cough. ⁶² ⁴¹	Ilbay A...Unal S	36326303	2022
4	Surveillance on the adverse events following immunization with the pentavalent vaccine in Zhejiang, China. ⁶²	Pan X...Hu Y	35108152	2022
5	Neuroprotective, Anti-inflammatory Effect of Furanochrome, Visnagin Against Middle Cerebral Ischemia-Induced Rat Model. ⁶²	Tian Q...Liu J	35819694	2022
6	Gaps in knowledge about the vaccine coverage of immunocompromised children: a scoping review. ⁶²	MacDonald SE...Burton C	34270376	2022
7	Pertussis toxin neutralizing antibody response after an acellular booster vaccination in Dutch and Finnish participants of different age groups. ⁶²	Knuutila A...PERISCOPE Consortium	35286231	2022
8	Specialized pro-resolvin mediators induce cell growth and improve wound repair in intestinal epithelial Caco-2 cell cultures. ⁶²	Storniolo CE...Moreno JJ	36427427	2022
9	The indirect impact of control measures in COVID-19 pandemic on the incidence of other infectious diseases in China. ⁶²	Song S...Lin A	35722540	2022
10	Historical trends in mortality from "older" vaccine-preventable diseases, Colombia: implications for elimination and control. ⁶²	Arango-Usuga C...Hincapie-Palacio D	36423493	2022
11	Common issues and improvement solution of vaccine hesitancy in children with underlying neurological conditions: Experience from one National Children's Medical Center in China. ⁶²	Feng T...Zeng M	36470687	2022
12	The role of bactericidal and opsonic activity in immunity against Bordetella pertussis. ⁶²	Blanc P...Renauld-Mongenie G	36369768	2022
13	Genetic predisposition to adverse events in Chinese children aged 3-24 months after diphtheria, tetanus, acellular pertussis and haemophilus influenzae type b combined vaccination. ⁶²	Ma Y...Chen D	36328952	2022
14	Novel approaches to reactivate pertussis immunity. ⁶²	Blanchard-Rohner G	36400443	2022
15	Genomic dissection of the microevolution of Australian epidemic Bordetella pertussis. ⁶²	Xu Z...Lan R	35543519	2022
16	Diphtheria-tetanus-pertussis (DTP) vaccination: understanding the perspectives and expectations of parents and healthcare professionals in France and India. ⁶²	Bakhache P...Turriani E	34435544	2022
17	Experience and attitudes on vaccinations recommended during pregnancy: survey on an Italian sample of women and consultant gynecologists. ⁶²	Scatigna M...Giuliani AR	33956557	2022
18	Maternal immunization: trends in South and Southeast Asian countries. ⁶²	Kamath GD...Sathyanarayanan S	34517746	2022
19	Near-infrared photoimmunotherapy induced tumor cell death enhances tumor dendritic cell migration. ⁶²	Moriya T...Tomura M	35624180	2022
20	The progress of postapproval clinical studies on Sabin IPV. ⁶²	Shi L...Sun M	34213408	2022
21	A_2A R mediated modulation in IP₃ levels altering the [Ca²⁺]_i through cAMP-dependent PKA signalling pathway. ⁶²	Barodia SK...Luthra PM	36084905	2022
22	Bacterial NadQ (COG4111) is a Nudix-like, ATP-responsive regulator of NAD biosynthesis. ⁶²	Minazzato G...Raffaelli N	36332744	2022
23	Review of scientific evidence to support recommendations of the full-dose DTaP-IPV vaccination in pre-school age children in Italy. ⁶²	Bechini A...Boccalini S	36178008	2022
24	Altruistic Vaccination: Insights from Two Focus Group Studies. ⁶²	Kraaijeveld SR...Mulder BC	36454320	2022
25	Lot-to-lot consistency of a hexavalent DTwP-IPV-HB-PRP∼T vaccine and non-inferiority to separate DTwP-HB-PRP∼T and IPV antigen-matching vaccines at 6-8, 10-12, and 14-16 weeks of age co-administered with oral rotavirus vaccine in healthy infants in India: A multi-center, randomized, controlled study. ⁶²	Mangarule S...Noriega F	36164460	2022
26	Conditional probability and ratio-based approaches for mapping the coverage of multi-dose vaccines. ⁶²	Utazi CE...Sahu SK	36129171	2022
27	Safety evaluation on concomitant immunization with inactivated poliomyelitis vaccine produced from Sabin strains and other vaccines (from 2015 to 2020). ⁶²	Deng Y...Yang J	35258415	2022
28	Proteomic characteristics of plasma and blood cells in natural aging rhesus monkeys. ⁶²	Wu N...Lu J	36037246	2022
29	Maternal vaccination-current status, challenges, and opportunities. ⁶²	Kurasawa K	36444417	2022
30	Clinic-level differences in human papillomavirus vaccination rates among rural and urban Oregon primary care clinics. ⁶²	Hatch BA...Carney PA	36396353	2022
31	Protecting the Offspring, the Gift of Maternal Immunization: Current Status and Future Perspectives. ⁶²	Lagousi T...Spoulou V	36423047	2022
32	A high-dimensional cytometry atlas of peripheral blood over the human life span. ⁶²	Jalali S...Pellicci DG	36218032	2022
33	Knowledge of, and attitudes towards, adult vaccination among General Practitioners in Piedmont, Italy: results from a cross-sectional study. ⁶²	Pizzini S...Morato P	35076653	2022
34	Estimation of vaccine effectiveness using the screening method. ⁶²	Farrington CP	36326585	2022
35	Reductions in stillbirths and preterm birth in COVID-19 vaccinated women: a multi-center cohort study of vaccination uptake and perinatal outcomes. ⁶²	Hui L...Walker SP	36336084	2022
36	Vaccination coverage in Italian children and antimicrobial resistance: an ecological analysis. ⁶²	Maugeri A...Agodi A	36352471	2022
37	Non-immunization associated with increased risk of sudden unexpected death in infancy: A national case-control study. ⁶²	Deschanvres C...OMIN Study Group	36460531	2022
38	Effectiveness of Bacille Calmette-Guerin vaccination policies in reducing infection and mortality of COVID-19: a systematic review. ⁶²	Obnial JC...Cunanan E	36336688	2022
39	Subnational Gender Inequality and Childhood Immunization: An Ecological Analysis of the Subnational Gender Development Index and DTP Coverage Outcomes across 57 Countries. ⁶²	Johns NE...Hosseinpoor AR	36423046	2022
40	Vaccination in pregnancy: Healthcare provider attitudes and practices. ⁶²	Rodriguez GF...Potter J	36352834	2022
41	Use of catch-up vaccinations in the second year of life (2YL) platform to close immunity gaps: A secondary DHS analysis in Pakistan, Philippines, and South Africa. ⁶²	Manandhar P...Sodha SV	36396512	2022
42	Negative Control Exposures: Causal Effect Identifiability and Use in Probabilistic-bias and Bayesian Analyses With Unmeasured Confounders. ⁶²	Flanders WD...Goodman M	35895515	2022
43	Tdap-HPV vaccination bundling in the USA: Trends, predictors, and implications for vaccine series completion. ⁶²	Zhu Y...Sonawane K	36007751	2022
44	The impact of women's political representation on child health outcomes during 1990-2020: Evidence from a global dataset. ⁶²	Rustagi N...Akter S	36201993	2022
45	A1 Adenosine Receptor Activation Inhibits P2X3 Receptor-Mediated ATP Currents in Rat Dorsal Root Ganglion Neurons. ⁶²	Hao JW...Hu WP	36074232	2022
46	Effect of text message communication on patient presentation for an influenza vaccination in a community-based pharmacy setting. ⁶²	Cabatit BC...Goode JR	35973934	2022
47	Routine childhood vaccination in India from 2005-2006 to 2015-2016: Temporal trends and geographic variation. ⁶²	Nayar R...Deo S	36280561	2022
48	Routine Vaccination Coverage - Worldwide, 2021. ⁶²	Rachlin A...Wallace AS	36327156	2022
49	Spatial distribution, determinants and trends of full vaccination coverage in children aged 12-59 months in Peru: A subanalysis of the Peruvian Demographic and Health Survey. ⁶²	Al-Kassab-Cordova A...Maguina JL	36368757	2022
50	Mapping the distribution of zero-dose children to assess the performance of vaccine delivery strategies and their relationships with measles incidence in Nigeria. ⁶²	Utazi CE...Cutts FT	36414476	2022

Sources

Genes for Pertussis

Genes related to Pertussis (0 elite genes):

(show all 37)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	OPRM1	Opioid Receptor Mu 1	Protein Coding	28.82	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Functions Drugs & Compounds (show sections)
2	GNA14	G Protein Subunit Alpha 14	Protein Coding	24.57	GeneCards inferred via : Publications Summaries Functions (show sections)
3	TLR4	Toll Like Receptor 4	Protein Coding	23.53	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Drugs & Compounds (show sections)
4	ADCY10	Adenylate Cyclase 10	Protein Coding	22.55	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Drugs & Compounds (show sections)
5	CCL2	C-C Motif Chemokine Ligand 2	Protein Coding	21.76	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Drugs & Compounds (show sections)
6	GNAZ	G Protein Subunit Alpha Z	Protein Coding	21.2	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Summaries (show sections)
7	CCL5	C-C Motif Chemokine Ligand 5	Protein Coding	21.04	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Drugs & Compounds (show sections)
8	MAPK1	Mitogen-Activated Protein Kinase 1	Protein Coding	20.97	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Drugs & Compounds (show sections)
9	ADORA1	Adenosine A1 Receptor	Protein Coding	20.94	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Drugs & Compounds (show sections)
10	GNAI1	G Protein Subunit Alpha I1	Protein Coding	20.77	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Drugs & Compounds (show sections)
11	GNAQ	G Protein Subunit Alpha Q	Protein Coding	20.76	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Functions (show sections)
12	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	20.69	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Drugs & Compounds (show sections)
13	CXCR4	C-X-C Motif Chemokine Receptor 4	Protein Coding	20.61	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Drugs & Compounds (show sections)
14	ITGB2	Integrin Subunit Beta 2	Protein Coding	20.49	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Drugs & Compounds (show sections)
15	SST	Somatostatin	Protein Coding	20.43	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Drugs & Compounds (show sections)
16	FPR1	Formyl Peptide Receptor 1	Protein Coding	20.43	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Drugs & Compounds (show sections)
17	GNA15	G Protein Subunit Alpha 15	Protein Coding	20.39	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Functions (show sections)
18	EGF	Epidermal Growth Factor	Protein Coding	20.36	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Drugs & Compounds (show sections)
19	JUN	Jun Proto-Oncogene, AP-1 Transcription Factor Subunit	Protein Coding	20.34	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Drugs & Compounds (show sections)
20	CCL11	C-C Motif Chemokine Ligand 11	Protein Coding	20.34	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Drugs & Compounds (show sections)
21	SRC	SRC Proto-Oncogene, Non-Receptor Tyrosine Kinase	Protein Coding	20.15	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Drugs & Compounds (show sections)
22	PIK3CG	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma	Protein Coding	20.07	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Drugs & Compounds (show sections)
23	FOS	Fos Proto-Oncogene, AP-1 Transcription Factor Subunit	Protein Coding	20.02	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Drugs & Compounds (show sections)
24	STAT3	Signal Transducer And Activator Of Transcription 3	Protein Coding	19.99	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Drugs & Compounds (show sections)
25	C5AR1	Complement C5a Receptor 1	Protein Coding	19.98	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Drugs & Compounds (show sections)
26	CXCL12	C-X-C Motif Chemokine Ligand 12	Protein Coding	19.83	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Drugs & Compounds (show sections)
27	VIP	Vasoactive Intestinal Peptide	Protein Coding	19.74	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Drugs & Compounds (show sections)
28	ITGAL	Integrin Subunit Alpha L	Protein Coding	19.57	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Drugs & Compounds (show sections)
29	ITGA4	Integrin Subunit Alpha 4	Protein Coding	19.48	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Drugs & Compounds (show sections)
30	LPAR1	Lysophosphatidic Acid Receptor 1	Protein Coding	19.28	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Drugs & Compounds (show sections)
31	PTK2B	Protein Tyrosine Kinase 2 Beta	Protein Coding	18.75	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Drugs & Compounds (show sections)
32	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	18.09	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Drugs & Compounds (show sections)
33	HSPG2	Heparan Sulfate Proteoglycan 2	Protein Coding	17.33	GeneCards inferred via : Publications Drugs & Compounds (show sections)
34	MAPK10	Mitogen-Activated Protein Kinase 10	Protein Coding	16.87	GeneCards inferred via : Publications Drugs & Compounds (show sections)
35	NPY	Neuropeptide Y	Protein Coding	16.55	GeneCards inferred via : Publications Drugs & Compounds (show sections)
36	OPRD1	Opioid Receptor Delta 1	Protein Coding	16.48	GeneCards inferred via : Publications Drugs & Compounds (show sections)
37	SHC1	SHC Adaptor Protein 1	Protein Coding	15.77	GeneCards inferred via : Publications Drugs & Compounds (show sections)

Sources

Variations for Pertussis

Sources

Expression for Pertussis

Search GEO for disease gene expression data for Pertussis.

Sources

Pathways for Pertussis

Pathways related to Pertussis according to GeneCards Suite gene sharing:

(show top 50) (show all 116)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	14.04	TLR4 OPRM1 MAPK1 JUN ITGB2 FPR1
2	Apoptotic Pathways in Synovial Fibroblasts ⁶⁴ Show member pathways Actin-Based Motility by Rho Family GTPases ⁶⁴ Cellular Apoptosis Pathway ⁶⁴ DHA Signaling ⁶⁴ eIF2 Pathway ⁶⁴ ERK5 Signaling ⁶⁴ Glioma Invasiveness ⁶⁴ Mitochondrial Apoptosis ⁶⁴ Nuclear Receptor Activation by Vitamin-A ⁶⁴ p53 Mediated Apoptosis ⁶⁴ PPAR Pathway ⁶⁴ Rac1 Pathway ⁶⁴ Rap1 Pathway ⁶⁴ Telomerase Components in Cell Signaling ⁶⁴	13.91	MAPK1 JUN ITGB2 GNAZ GNAI1 GNA15
3	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.82	AKT1 CCL11 CCL2 CCL5 CXCR4 EGF
4	GPCR Pathway ⁶⁴ Show member pathways Breast Cancer Regulation by Stathmin1 ⁶⁴ Estrogen Pathway ⁶⁴ NFAT in Immune Response ⁶⁴ P2Y Receptor Signaling ⁶⁴ Pancreatic Adenocarcinoma ⁶⁴ Paxillin Interactions ⁶⁴ Ras Pathway ⁶⁴	13.77	MAPK1 JUN ITGB2 GNAZ GNAI1 GNA15
5	MIF Mediated Glucocorticoid Regulation ⁶⁴ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁴ Endothelin-1 Signaling Pathway ⁶⁴ Glucocorticoid Receptor Signaling ⁶⁴ IL-6 Pathway ⁶⁴ MIF Regulation of Innate Immune Cells ⁶⁴ NFAT Signaling and Lymphocyte Interactions ⁶⁴ Overview of proinflammatory and profibrotic mediators ⁷⁴ PEDF Induced Signaling ⁶⁴ PGC1Alpha Pathway ⁶⁴ RAR-Gamma-RXR-Alpha Degradation ⁶⁴ STAT3 Pathway ⁶⁴	13.64	AKT1 CCL11 CCL2 CCL5 CXCR4 GNA14
6	Activation of cAMP-Dependent PKA ⁶⁴ Show member pathways Activation of PKA through GPCR ⁶⁴ cAMP Pathway ⁶⁴ PKA Signaling ⁶⁴	13.63	MAPK1 GNAZ GNAI1 GNA15 GNA14 EGF
7	TGF-Beta Pathway ⁶⁴ Show member pathways JAK-STAT Pathway ⁶⁴ JNK Pathway ⁶⁴ MAPK Family Pathway ⁶⁴ Regulation of eIF4 and p70S6K ⁶⁴ SOCS Pathway ⁶⁴	13.57	MAPK1 JUN ITGB2 GNA15 GNA14 EGF
8	Prolactin Signaling ⁶⁴ Show member pathways Development Prolactin receptor signaling ²² EGFR Inhibitor Pathway, Pharmacodynamics ⁶⁰ EGFR tyrosine kinase inhibitor resistance ⁷⁴ ErbB Family Pathway ⁶⁴ ErbB signaling pathway ⁷⁴ ErbB2-ErbB3 Heterodimers ⁶⁴ ErbB4 Pathway ⁶⁴ Estrogen-stimulated signaling through PRKCZ ⁶⁶ Glioblastoma Multiforme ⁶⁴ Glioblastoma signaling pathways ⁷⁴ Growth Hormone Signaling ⁶⁴ HMGB1 Pathway ⁶⁴ IL-2 Pathway ⁶⁴ LPS Stimulated MAPK Signaling ⁶⁴ PACAP Signaling ⁶⁴ PI3K Signaling in B-Lymphocyte ⁶⁴ TCA cycle nutrient use and invasiveness of ovarian cancer ⁷⁴ Thrombopoietin Pathway ⁶⁴ TREM1 Pathway ⁶⁴ UVA-Induced MAPK Signaling ⁶⁴ UVB-Induced MAPK Signaling ⁶⁴ UVC-Induced MAPK Signaling ⁶⁴	13.55	AKT1 EGF GNAI1 GNAQ GNAZ JUN
9	Class A/1 (Rhodopsin-like receptors) ⁶⁶ Show member pathways GPCR ligand binding ⁶⁶ GPCRs, class A rhodopsin-like ⁷⁴ Peptide GPCRs ⁷⁴ Peptide ligand-binding receptors ⁶⁶	13.46	ADORA1 CCL11 CCL2 CCL5 CXCR4 FPR1
10	CREB Pathway ⁶⁴ Show member pathways Activation of PKC through GPCR ⁶⁴ Intracellular Calcium Signaling ⁶⁴ IP3 Pathway ⁶⁴	13.4	MAPK1 GNAZ GNAI1 GNA15 GNA14 EGF
11	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.4	OPRM1 MAPK1 JUN ITGB2 FPR1 CCL5
12	PAK Pathway ⁶⁴ Show member pathways Antioxidant Action of Vitamin-C ⁶⁴ Epithelial Adherens Junctions ⁶⁴	13.38	MAPK1 JUN EGF CXCR4 CCL5 CCL2
13	Response to elevated platelet cytosolic Ca2+ ⁶⁶ Show member pathways Disinhibition of SNARE formation ⁶⁶ Hemostasis ⁶⁶ Platelet activation, signaling and aggregation ⁶⁶ Platelet degranulation ⁶⁶	13.37	AKT1 EGF GNA14 GNA15 GNAI1 GNAQ
14	ADORA2B mediated anti-inflammatory cytokines production ⁶⁶ Show member pathways Alpha-Adrenergic Signaling ⁶⁴ Androgen receptor signaling pathway ⁷⁴ Anti-inflammatory response favouring Leishmania parasite infection ⁶⁶ Beta-agonist/Beta-blocker Pathway, Pharmacodynamics ⁶⁰ CD163 mediating an anti-inflammatory response ⁶⁶ Cytoskeleton remodeling Role of PKA in cytoskeleton reorganisation ²² G alpha (z) signalling events ⁶⁶ G protein signaling pathways ⁷⁴ Glucagon signaling in metabolic regulation ⁶⁶ GPER1 signaling ⁶⁶ Hedgehog Signaling in Mammals ⁶⁴ Leishmania infection ⁶⁶ Leishmania parasite growth and survival ⁶⁶ LTC4-CYSLTR mediated IL4 production ⁶⁶ Relaxin Pathway ⁶⁴ Signal transduction cAMP signaling ²²	13.34	MAPK1 JUN GNAZ GNAQ GNAI1 GNA15
15	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.29	AKT1 CCL11 CCL2 CCL5 CXCR4 EGF
16	Integrin Pathway ⁶⁴ Show member pathways FAK1 Signaling ⁶⁴ GnRH Signaling ⁶⁴ Inhibition of Angiogenesis by TSP1 ⁶⁴ Transendothelial Migration of Leukocytes ⁶⁴ UPA-UPAR Pathway ⁶⁴	13.21	MAPK1 JUN ITGB2 GNAZ GNAI1 GNA15
17	Phospholipase-C Pathway ⁶⁴ Show member pathways PTEN Pathway ⁶⁴	13.16	AKT1 EGF GNA14 GNA15 GNAI1 GNAZ
18	Sweet Taste Signaling ⁶⁴ Show member pathways Bitter Taste Signaling ⁶⁴ Cellular Effects of Sildenafil ⁶⁴ Melatonin Signaling ⁶⁴ Sperm Motility ⁶⁴	13.14	MAPK1 JUN GNAZ GNAI1 GNA15 GNA14
19	p70S6K Signaling ⁶⁴ Show member pathways mTOR Pathway ⁶⁴ Renin-Angiotensin Pathway ⁶⁴	13.14	AKT1 CCL2 EGF GNA14 GNA15 GNAI1
20	GPCR downstream signalling ⁶⁶ Show member pathways G alpha (i) signalling events ⁶⁶ G alpha (q) signalling events ⁶⁶ Signaling by GPCR ⁶⁶	13.11	SST OPRM1 MAPK1 GNAZ GNAQ GNAI1
21	Actin Nucleation by ARP-WASP Complex ⁶⁴ Show member pathways Actin Nucleation and Branching ⁶⁴ CDC42 Pathway ⁶⁴ RhoA Pathway ⁶⁴	13.04	GNA14 GNA15 GNAI1 GNAZ ITGB2 JUN
22	TNFR1 Pathway ⁶⁴ Show member pathways Apoptosis ⁷⁴ Apoptosis and survival TNFR1 signaling pathway ²² Apoptosis modulation by HSP70 ⁷⁴ Apoptosis through Death Receptors ⁶⁴ Apoptotic Pathways Triggered By HIV1 ⁶⁴ Ceramide signaling pathway ⁶¹ DR3 Signaling ⁶⁴ GITR Pathway ⁶⁴ HIV-1 Nef: Negative effector of Fas and TNF-alpha ⁶¹ Stimulation of the cell death response by PAK-2p34 ⁶⁶ TNF Signaling ⁶⁴ TNF-related weak inducer of apoptosis (TWEAK) signaling pathway ⁷⁴ TRAIL Pathway ⁶⁴ TWEAK Pathway ⁶⁴	13	MAPK1 JUN GNAZ GNAQ GNAI1 EGF
23	Signal Transduction ⁶⁶	12.99	SST OPRM1 MAPK1 JUN GNAZ GNAQ
24	Sertoli-Sertoli Cell Junction Dynamics ⁶⁴ Show member pathways Epithelial Tight Junctions ⁶⁴ Germ Cell-Sertoli Cell Junction Dynamics ⁶⁴	12.97	MAPK1 JUN ITGB2 AKT1 ADCY10
25	NFAT and Cardiac Hypertrophy ⁶⁴ Show member pathways IGF1R Signaling ⁶⁴ Signaling Involved in Cardiac Hypertrophy ⁶⁴	12.96	MAPK1 JUN ITGB2 GNAI1 GNA15 GNA14
26	Toll-like receptor signaling pathway ⁷⁴ Show member pathways Hepatitis B infection ⁷⁴ Measles virus infection ⁷⁴ Regulation of toll-like receptor signaling pathway ⁷⁴	12.91	TLR4 MAPK1 JUN CCL5 AKT1
27	Beta-Adrenergic Signaling ⁶⁴ Show member pathways CDK5 Pathway ⁶⁴ Erythropoietin Pathway ⁶⁴ Insulin Pathway ⁷⁰ Insulin Receptor Pathway ⁶⁴	12.85	MAPK1 JUN ITGB2 GNAZ GNAI1 GNA15
28	Calmodulin induced events ⁶⁶ Show member pathways Ca-dependent events ⁶⁶ CaM pathway ⁶⁶ CaMK IV-mediated phosphorylation of CREB ⁶⁶ Cam-PDE 1 activation ⁶⁶ CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde ⁶⁶ DAG and IP3 signaling ⁶⁶ G-protein mediated events ⁶⁶ Opioid Signalling ⁶⁶ PLC beta mediated events ⁶⁶ Signal transduction Calcium signaling ²²	12.84	OPRM1 MAPK1 GNAQ GNAI1 GNA15 GNA14
29	Development Angiotensin activation of ERK ²² Show member pathways Cell adhesion Integrin inside-out signaling ²² Development ACM2 and ACM4 activation of ERK ²² Development Angiotensin signaling via PYK2 ²² Development EDNRB signaling ²² Development EPO-induced MAPK pathway ²² Development G-Proteins mediated regulation MARK-ERK signaling ²² Signal transduction IP3 signaling ²²	12.84	MAPK1 JUN ITGB2 GNAZ GNAQ GNAI1
30	fMLP Pathway ⁶⁴ Show member pathways CXCR4 Pathway ⁶⁴ Huntington's Disease Pathway ⁶⁴ Internalin Pathway ⁶⁴ Signal transduction Activation of PKC via G-Protein coupled receptor ²²	12.8	MAPK1 JUN GNAZ GNAI1 GNA15 GNA14
31	Malignant pleural mesothelioma ⁷⁴	12.78	AKT1 CCL2 CCL5 EGF ITGB2 JUN
32	G-AlphaQ Signaling ⁶⁴ Show member pathways G-AlphaI Signaling ⁶⁴ PAR4-mediated thrombin signaling events ⁶¹ Thrombin Signaling ⁶⁴	12.77	MAPK1 GNAZ GNAI1 GNA15 GNA14 EGF
33	CCR5 Pathway in Macrophages ⁶⁴ Show member pathways Androgen Signaling ⁶⁴ Chemokine Signaling ⁶⁴ Chemokine signaling pathway ⁷⁴	12.76	MAPK1 JUN GNAI1 GNA15 GNA14 CXCR4
34	CNTF Signaling ⁶⁴ Show member pathways Activation of the AP-1 family of transcription factors ⁶⁶ FLT3 Signaling ⁶⁴ G-protein signaling Ras family GTPases in kinase cascades (scheme) ²² Host-pathogen interaction of human coronaviruses - MAPK signaling ⁷⁴ IL-3 Pathway ⁶⁴ Immune response Oncostatin M signaling via MAPK in human cells ²² Inhibition of exosome biogenesis and secretion by Manumycin A in CRPC cells ⁷⁴ MAPK cascade ⁷⁴ Nur77-Induced AICD in Macrophage ⁶⁴ OSM Pathway ⁶⁴	12.74	TLR4 MAPK1 JUN CCL2 AKT1
35	4-1BB Pathway ⁶⁴ Show member pathways CD27 Pathway ⁶⁴ CD40 Signaling ⁶⁴ CMV and MAPK Pathways ⁶⁴ NF-KappaB Activation by EBV ⁶⁴ NF-kappaB Activation by Viruses ⁶⁴ PKR Pathway ⁶⁴ SUMO Pathway ⁶⁴ TNFR2 Pathway ⁶⁴	12.74	MAPK1 JUN EGF CXCR4 AKT1
36	G-protein signaling G-Protein alpha-i signaling cascades ²² Show member pathways Development Beta-adrenergic receptors regulation of ERK ²² G-protein signaling G-Protein alpha-s signaling cascades ²² G-protein signaling G-Protein beta/gamma signaling cascades ²² Signaling in Gap Junctions ⁶⁴	12.74	MAPK1 JUN GNAZ GNAI1 GNA15 EGF
37	G-Beta Gamma Signaling ⁶⁴ Show member pathways CRHR Pathway ⁶⁴ GHRH Signaling ⁶⁴	12.71	MAPK1 JUN GNAZ GNAI1 GNA15 GNA14
38	TNF Superfamily - Human Ligand-Receptor Interactions and their Associated Functions ⁶⁵ Show member pathways 14-3-3 Induced Apoptosis ⁶⁴ TNF Superfamily Pathway ⁶⁴ TNFs bind their physiological receptors ⁶⁶ TRAF Pathway ⁶⁴	12.7	TLR4 MAPK1 JUN GNAQ AKT1
39	Beta-2 adrenergic-dependent CFTR expression ²² Show member pathways CREB1 phosphorylation through the activation of Adenylate Cyclase ⁶⁶ Development Beta-adrenergic receptors signaling via cAMP ²² Development Role of Activin A in cell differentiation and proliferation ²² FCGR activation ⁶⁶ FCGR3A-mediated IL10 synthesis ⁶⁶ Inhibitory action of Lipoxin A4 on PDGF, EGF and LTD4 signaling ²² Major receptors targeted by epinephrine and norepinephrine ⁷⁴ Neurophysiological process PGE2-induced pain processing ²² PKA activation ⁶⁶ PKA activation in glucagon signalling ⁶⁶ PKA-mediated phosphorylation of CREB ⁶⁶	12.69	GNAZ GNAQ GNAI1 EGF ADCY10
40	Myometrial relaxation and contraction pathways ⁷⁴ Show member pathways Calcium regulation in cardiac cells ⁷⁴	12.58	JUN GNAZ GNAQ GNAI1
41	Thromboxane signalling through TP receptor ⁶⁶ Show member pathways ADP signalling through P2Y purinoceptor 1 ⁶⁶ ADP signalling through P2Y purinoceptor 12 ⁶⁶ Adrenaline,noradrenaline inhibits insulin secretion ⁶⁶ Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding ⁶⁶ Development Angiotensin signaling via beta-Arrestin ²² G-protein activation ⁶⁶ Signal amplification ⁶⁶ Thrombin signalling through proteinase activated receptors (PARs) ⁶⁶	12.58	OPRM1 MAPK1 GNAQ GNAI1 GNA15 GNA14
42	Human Embryonic Stem Cell Pluripotency ⁶⁴ Show member pathways Factors Promoting Cardiogenesis in Vertebrates ⁶⁴	12.57	GNAZ GNAI1 GNA15 GNA14 AKT1
43	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ⁶¹	12.56	MAPK1 JUN EGF AKT1
44	Integration of energy metabolism ⁶⁶ Show member pathways Acetylcholine regulates insulin secretion ⁶⁶ AMPK inhibits chREBP transcriptional activation activity ⁶⁶ ChREBP activates metabolic gene expression ⁶⁶ Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion ⁶⁶ Free fatty acids regulate insulin secretion ⁶⁶ Glucagon-like Peptide-1 (GLP1) regulates insulin secretion ⁶⁶ Intracellular metabolism of fatty acids regulates insulin secretion ⁶⁶ PKA-mediated phosphorylation of key metabolic factors ⁶⁶ PP2A-mediated dephosphorylation of key metabolic factors ⁶⁶ Regulation of insulin secretion ⁶⁶ Saturated fatty acid biosynthesis ²²	12.55	GNAQ GNAI1 GNA15 GNA14
45	VEGF Pathway (Qiagen) ⁶⁴ Show member pathways CCKBR-Gastrin Stimulated Signaling ⁶⁴ Development VEGF-family signaling ²² Neurophilin interactions with VEGF and VEGFR ⁶⁶ VEGF and VEGFR signaling network ⁶¹ VEGF Family Ligands and Receptor Interactions ⁶⁴	12.53	TLR4 MAPK1 JUN EGF AKT1
46	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.52	MAPK1 JUN EGF AKT1
47	EphB-EphrinB Signaling ⁶⁴ Show member pathways Cytoskeleton remodeling Reverse signaling by ephrin B ²² Ephrin-Eph Signaling ⁶⁴	12.49	MAPK1 GNAZ GNAI1 GNA15 GNA14 CXCR4
48	WNT Signaling ⁶⁴	12.49	MAPK1 JUN GNAZ GNAI1 GNA15 GNA14
49	MAPK signaling pathway ⁷⁴	12.47	MAPK1 JUN EGF AKT1
50	Development VEGF signaling via VEGFR2 - generic cascades ²² Show member pathways Development VEGF signaling and activation ²² VEGF - VEGF R2 Signaling Pathways ⁶⁵	12.46	MAPK1 JUN CCL2 AKT1

Sources

GO Terms for Pertussis

Cellular components related to Pertussis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	heterotrimeric G-protein complex	GO:0005834	9.32	GNAZ GNAQ GNAI1 GNA15 GNA14

Biological processes related to Pertussis according to GeneCards Suite gene sharing:

(show all 22)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of ERK1 and ERK2 cascade	GO:0070374	10.21	CCL11 CCL2 CCL5 JUN OPRM1 TLR4
2	inflammatory response	GO:0006954	10.21	TLR4 ITGB2 FPR1 CXCR4 CCL5 CCL2
3	cellular response to tumor necrosis factor	GO:0071356	10.18	MAPK1 CCL5 CCL2 CCL11 AKT1
4	cellular response to type II interferon	GO:0071346	10.17	TLR4 CCL5 CCL2 CCL11
5	neutrophil chemotaxis	GO:0030593	10.16	ITGB2 CCL5 CCL2 CCL11
6	positive regulation of endothelial cell proliferation	GO:0001938	10.15	AKT1 CCL11 EGF JUN
7	chemotaxis	GO:0006935	10.11	MAPK1 FPR1 CXCR4 CCL5 CCL2 CCL11
8	ERK1 and ERK2 cascade	GO:0070371	10.1	CCL11 EGF MAPK1 TLR4
9	protein kinase B signaling	GO:0043491	10.08	CCL5 CCL2 AKT1
10	monocyte chemotaxis	GO:0002548	10.08	CCL5 CCL2 CCL11
11	chemokine-mediated signaling pathway	GO:0070098	10.08	CXCR4 CCL5 CCL2 CCL11
12	cellular response to reactive oxygen species	GO:0034614	10.07	MAPK1 JUN AKT1
13	cellular response to cadmium ion	GO:0071276	10.06	MAPK1 JUN AKT1
14	lymphocyte chemotaxis	GO:0048247	10.05	CCL11 CCL2 CCL5
15	lipopolysaccharide-mediated signaling pathway	GO:0031663	10.02	AKT1 CCL2 CCL5 MAPK1 TLR4
16	eosinophil chemotaxis	GO:0048245	10	CCL5 CCL2 CCL11
17	adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	GO:0007193	10	OPRM1 GNAZ GNAI1 ADORA1
18	signal transduction	GO:0007165	10	ADORA1 AKT1 CCL11 CCL2 CCL5 CXCR4
19	action potential	GO:0001508	9.99	GNAQ GNA15 GNA14
20	adenylate cyclase-modulating G protein-coupled receptor signaling pathway	GO:0007188	9.93	FPR1 GNA14 GNA15 GNAI1 GNAQ GNAZ
21	positive regulation of nitric oxide biosynthetic process	GO:0045429	9.88	TLR4 OPRM1 ITGB2 AKT1
22	G protein-coupled receptor signaling pathway	GO:0007186	9.7	SST OPRM1 GNAZ GNAQ GNAI1 GNA15

Molecular functions related to Pertussis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	G protein-coupled receptor binding	GO:0001664	10	ADORA1 FPR1 GNA14 GNA15 GNAI1 GNAQ
2	nucleotide binding	GO:0000166	9.97	MAPK1 GNAZ GNAQ GNAI1 GNA15 GNA14
3	chemokine activity	GO:0008009	9.88	CCL5 CCL2 CCL11
4	CCR chemokine receptor binding	GO:0048020	9.73	CCL5 CCL2 CCL11
5	G protein-coupled serotonin receptor binding	GO:0031821	9.62	GNAZ GNAI1
6	G-protein beta/gamma-subunit complex binding	GO:0031683	9.4	GNAZ GNAQ GNAI1 GNA15 GNA14 ADORA1
7	guanyl nucleotide binding	GO:0019001	9.35	GNAZ GNAQ GNAI1 GNA15 GNA14